Acute severe community-acquired pneumonia: respiratory virus panel · ICU Topics

ICU scene showing a multiplex respiratory viral PCR panel result, a chest X-ray with bilateral viral infiltrates, a nasopharyngeal swab, and oseltamivir and supportive respiratory support running, clinical-blue lighting — FigureViral CAP — influenza, SARS-CoV-2 and RSV cause severe lower-respiratory infection and predispose to bacterial superinfection. A rapid multiplex respiratory PCR panel guides antiviral therapy (oseltamivir for influenza) and isolation; secondary bacterial pneumonia remains the dominant killer.

Viral lower respiratory infection with alveolar injury and secondary bacterial superinfection — FigurePathophysiology — viral cytopathic injury, diffuse alveolar damage risk, and bacterial superinfection (S. aureus, pneumococcus) remain the dominant killers after the viral prodrome.

Management of severe viral CAP with antivirals isolation and organ support — FigureManagement — rapid multiplex respiratory PCR, early oseltamivir if influenza possible, isolation, oxygen/HFNC/ventilation ladder, and low threshold for secondary bacterial cover when shock or lobar consolidation appears.

In one line

Viral CAP: 15-30% of severe CAP. The common ICU viruses are influenza A/B, RSV, SARS-CoV-2, adenovirus, rhinovirus, parainfluenza, hMPV, coronavirus, enterovirus, bocavirus. Diagnosis: multiplex respiratory virus PCR panel (nasopharyngeal swab or BAL) — results in ~1 hour. Treatment: antivirals where they exist (oseltamivir for influenza, remdesivir for COVID-19, ribavirin for RSV in the immunocompromised), supportive ICU care, and corticosteroids for severe COVID-19 pneumonia. Always add antibiotics empirically — bacterial co-infection is 25-50%, and a positive viral PCR does not prove the virus is the cause (asymptomatic shedding and prolonged shedding are common). Procalcitonin is a useful bacterial biomarker adjunct but does not exclude co-infection. Send respiratory PCR in ALL severe CAP during viral season.[1][2]

Why the respiratory virus panel matters in the ICU

Note

The shift from 'probably viral, treat supportively' to 'this virus, this drug'

For decades, severe CAP was managed empirically — a viral aetiology was a diagnosis of exclusion, confirmed (if at all) days later by culture or weeks later by serology. Syndromic multiplex PCR panels (e.g. BioFire FilmArray, Luminex xTAG, Genmark eSensor, Cepheid Xpert) changed this: a single nasopharyngeal swab or BAL is tested for 10-20+ respiratory pathogens simultaneously, with a result in ~1 hour. This matters for three reasons. (1) Aetiological diagnosis — you can name the pathogen before the next antibiotic dose. (2) Antiviral selection — oseltamivir for influenza, remdesivir for SARS-CoV-2, ribavirin for RSV in the immunocompromised. (3) Infection control — a positive influenza/RSV/COVID result dictates cohorting, droplet/contact precautions and (for aerosol-generating procedures) negative-pressure isolation. The trade-off is that sensitivity now outpaces clinical specificity: the panel detects nucleic acid, not active disease, so asymptomatic shedding, prolonged shedding after a resolved infection, and true bacterial co-infection all complicate interpretation.[9][10]

Common respiratory viruses in ICU

Influenza A/B

#1 viral cause

Seasonal (winter). Antigenic drift (annual) and shift (pandemic).
Antiviral: oseltamivir 75 mg PO BD x 5 days (start immediately, even if >48h in severe cases)
Bacterial co-infection: S. aureus (#1, often post-influenza), S. pneumoniae, H. influenzae
Vaccination: annual (best prevention)

SARS-CoV-2 (COVID-19)

Pandemic/ongoing

Antiviral: remdesivir 200 mg day 1 then 100 mg daily x 5-10 days (early disease). Limited benefit in late/ventilated patients.
Anti-inflammatory: dexamethasone 6 mg daily x 10 days (RECOVERY trial — reduces mortality in oxygen/ventilated patients)
Immunomodulator: tocilizumab (IL-6 receptor antagonist) for rapid respiratory deterioration + elevated CRP
Anticoagulation: prophylactic-dose LMWH (unless contraindicated) — COVID-associated coagulopathy

RSV

Infants and elderly

Severe in: infants, elderly, heart/lung disease, immunocompromised
Antiviral: ribavirin (aerosolised) — reserved for the immunocompromised; supportive care mainstay in immunocompetent adults
Palivizumab / nirsevimab (monoclonal antibodies) — prophylaxis for high-risk infants (not treatment)
Bronchodilators, supportive ventilation

Adenovirus

Immunocompromised / military recruits

Can cause severe necrotising pneumonia, especially in transplant recipients and neonates
Treatment: cidofovir (limited evidence) + IV immunoglobulin in severe disease
May shed for weeks after infection (interpret PCR with caution)

Human metapneumovirus (hMPV)

Similar to RSV

Clinically indistinguishable from RSV — bronchiolitis in children, pneumonia in elderly/immunocompromised
No specific antiviral — supportive care is the mainstay
Recognised only since 2001; identified by PCR, not by older antigen methods

Parainfluenza 1-4

Croup / pneumonia

Parainfluenza 1/2 — croup in children; type 3 — bronchiolitis and pneumonia
Pneumonia in the immunocompromised (esp. haematopoietic stem cell transplant) can be severe
Supportive care; DAS181 (sialidase) has limited evidence in immunocompromised pneumonia

Rhinovirus / enterovirus

Common cold pathogens

Usually mild (common cold) but a leading cause of CAP exacerbation in COPD/asthma
Can cause severe pneumonia in the immunocompromised
Frequently detected as asymptomatic carriage — interpret a positive result cautiously

Coronavirus (non-SARS) + bocavirus

Panel additions

Seasonal coronaviruses (229E, OC43, NL63, HKU1) cause mild URI but can precipitate CAP in frail patients
Human bocavirus — frequent co-detection in children; true pathogenicity in adults debated
Supportive care; no specific antiviral

CMV (immunocompromised only)

Transplant / advanced HIV

Not on standard CAP panels — send CMV PCR on BAL in the immunocompromised with interstitial infiltrates
Ganciclovir 5 mg/kg IV BD x 14-21 days (valganciclovir for step-down)
Often coexists with pneumonitis in stem-cell transplant recipients

[1] [2]

The multiplex respiratory virus panel — what it is and how it is used

How the syndromic respiratory PCR panel is used in the ICU

1. Specimen — nasopharyngeal swab (or BAL)

A flocked nasopharyngeal swab in viral transport medium is the standard specimen for upper-respiratory viruses. In intubated patients, **endotracheal aspirate or BAL** gives higher yield for lower-respiratory viruses (influenza, RSV, SARS-CoV-2, hMPV) and allows bacterial culture to be sent on the same sample. A BAL specimen is essential when suspecting **CMV/HSV pneumonitis** in the immunocompromised. Swab technique matters: an inadequate nasopharyngeal swab is the commonest cause of a false-negative.

2. Multiplex nucleic-acid amplification (PCR)

The sample is loaded onto a **syndromic multiplex panel** (e.g. BioFire FilmArray RP, Luminex xTAG/NxTAG, Genmark eSensor, Cepheid Xpert Xpress Flu/RSV). These platforms amplify and detect **influenza A/B (+ subtyping), RSV A/B, SARS-CoV-2, parainfluenza 1-4, adenovirus, rhinovirus/enterovirus, human metapneumovirus, coronaviruses (incl. endemic strains), human bocavirus, and sometimes Mycoplasma, Chlamydia and Bordetella**. Turnaround is ~1 hour on FilmArray; batched platforms a few hours.<Cite id="9" /><Cite id="10" />

3. Result interpretation in context

A positive result must be read against the pre-test probability and the limitations below. **One or more viruses detected** is common; the panel cannot distinguish colonisation/asymptomatic shedding from causative infection. **Cycle threshold (Ct)** is sometimes reported — a low Ct (high viral load) is more compatible with true infection, but thresholds vary by assay and Ct should not be over-interpreted in isolation.

4. Action — therapy, isolation, stewardship

Use the result to (a) **start or continue targeted antiviral therapy** (oseltamivir for influenza, remdesivir for COVID-19, ribavirin for RSV in the immunocompromised); (b) **set infection-control precautions** — droplet + contact for influenza/RSV, airborne/negative-pressure for aerosol-generating procedures; (c) **de-escalate antibiotics** if bacterial cultures/procalcitonin are reassuring AND the patient is improving; and (d) **cohort** patients with the same virus to preserve single rooms.

[9] [10] [9] [10]

Clinical utility of a confirmed viral diagnosis

Note

Four reasons a rapid viral result changes ICU management

A respiratory virus panel result is not academic — it drives four concrete decisions. (1) Aetiological diagnosis — naming the pathogen narrows the differential and explains the radiology (e.g. bilateral interstitial infiltrates with hMPV). (2) Antiviral therapy — oseltamivir for influenza (benefit even if started >48h in severe disease), remdesivir for early COVID-19, ribavirin for RSV in the immunocompromised, ganciclovir for CMV. (3) Infection control and isolation — cohorting by organism, droplet + contact precautions for influenza/RSV, airborne precautions for aerosol-generating procedures, and triggering public-health notification for novel/emerging viruses. (4) Antibiotic stewardship — in a stable, improving patient with a confident viral diagnosis and negative bacterial cultures, antibiotics can often be stopped earlier, shortening exposure and reducing resistance and C. difficile risk.[3][7]

Antiviral therapy decisions driven by the panel

Influenza A/B positive → oseltamivir

Oseltamivir 75 mg PO BD x 5 days (dose-adjusted if eGFR <30). Start immediately on suspicion in flu season; do not wait for the PCR. Meta-analysis of randomised trials shows symptom reduction and, in severe/hospitalised influenza, a mortality signal in favour of early treatment. Benefits persist even when started >48h in critically ill patients. Alternatives: zanamivir (inhaled, avoid in ventilated/obstructed airway), baloxavir (single dose; limited ICU data).<Cite id="8" />

SARS-CoV-2 positive → severity-stratified COVID therapy

Remdesivir 200 mg day 1 then 100 mg daily x 5-10 days benefits EARLY disease (first ~10 days, before the hyper-inflammatory phase). **Dexamethasone 6 mg daily x up to 10 days** reduces mortality in patients requiring oxygen or ventilation (RECOVERY). **Tocilizumab** (IL-6 receptor antagonist) for rapid respiratory deterioration with systemic inflammation/CRP elevation (REMAP-CAP). Add prophylactic-dose LMWH for COVID-associated coagulopathy.<Cite id="4" /><Cite id="5" /><Cite id="6" />

RSV positive + immunocompromised → consider ribavirin

Aerosolised ribavirin is reserved for RSV in transplant recipients / severely immunocompromised adults or infants with high-risk disease; in immunocompetent adults, supportive care is the mainstay. Healthcare-worker exposure to aerosolised ribavirin is a teratogenicity concern — administer in a scavenged circuit.

CMV positive (BAL) in immunocompromised → ganciclovir

Ganciclovir 5 mg/kg IV BD x 14-21 days, then valganciclovir for maintenance/step-down. Concurrent CMV DNAemia quantitation guides duration. Often combined with reduction of immunosuppression.

Adenovirus / hMPV / parainfluenza / rhinovirus → mainly supportive

No proven specific antiviral for most. Cidofovir has been used for severe adenovirus disease in transplant recipients. Treatment is supportive lung-protective ventilation, lung-protective fluid strategy, and treatment of bacterial co-infection.

[4] [5] [6] [8]

Antiviral and immunomodulatory evidence (COVID-19 and influenza)

2021

Dexamethasone reduces mortality in COVID-19 patients requiring oxygen or ventilation — RECOVERY

Multicentre, randomised, open-label, platform trial

Population: Hospitalised COVID-19 patients (n > 6000 in the dexamethasone arm)

Key finding

Mortality reduction confined to patients receiving respiratory support: ~one-third fewer deaths in invasively ventilated patients and ~one-fifth fewer in patients receiving oxygen alone. No benefit (possible harm) in patients not requiring oxygen.

[5]

2020

Remdesivir shortens recovery in early COVID-19 — ACTT-1

Double-blind, randomised, placebo-controlled trial

Population: Hospitalised adults with COVID-19 pneumonia (n = 1062)

Key finding

Median time to recovery shortened from 15 to 10 days. Benefit greatest in patients requiring low-flow oxygen; no mortality benefit in those already mechanically ventilated (late, hyper-inflammatory disease).

[4]

2021

Tocilizumab improves survival in critically ill COVID-19 — REMAP-CAP

Randomised, embedded, multifactorial, adaptive platform trial

Population: Critically ill adults with COVID-19 receiving respiratory or cardiovascular organ support

Key finding

Reduced 90-day mortality and more organ-support-free days. Benefit seen in patients with systemic hyper-inflammation (elevated CRP).

[6]

2015

Oseltamivir reduces symptom duration in adults with influenza — meta-analysis of RCTs

Meta-analysis of individual patient data from randomised controlled trials

Population: Adults with confirmed influenza treated within 48 hours of symptom onset

Key finding

Significant reduction in symptom duration; in the subgroup of patients with confirmed influenza and higher risk, reduced lower-respiratory-tract complications and hospitalisation.

[8]

Impact on antibiotic stewardship

Note

A viral diagnosis is a stewardship opportunity — not a licence to stop antibiotics

The strongest single argument for sending a respiratory virus panel in severe CAP is antibiotic stewardship. When a virus is identified, bacterial cultures are negative, the patient is improving, and procalcitonin is reassuring, antibiotics can frequently be stopped early — shortening exposure, reducing resistance selection pressure, lowering C. difficile risk, and cutting cost. The hazard: bacterial co-infection is common (25-50% in influenza and COVID-19), a positive viral PCR may coexist with genuine bacterial pneumonia, and procalcitonin can be normal early in bacterial sepsis. The safe rule is stop only when the bacterial workup is genuinely negative AND the patient is clinically improving — never on the viral result alone, and never simply because the PCT is low.[3][7]

[7]

Using the viral result for safe antibiotic de-escalation

1. Confirm the bacterial workup is negative

Blood cultures, sputum/ETT aspirate culture, urinary pneumococcal and Legionella antigen, and (if relevant) atypical serology all negative or non-contributory. A positive bacterial culture mandates continuing targeted antibiotics regardless of the viral result.

2. Confirm the viral result fits the clinical picture

A single positive virus with a compatible illness (interstitial infiltrates, viral prodrome, low procalcitonin) and high viral load supports a viral aetiology. Be cautious with rhinovirus/enterovirus/bocavirus, which are frequently carried asymptomatically.

3. Confirm the patient is clinically improving

Falling oxygen requirement, resolving fever, improving inflammatory markers, and haemodynamic stability. Do not de-escalate in a deteriorating patient even if the PCT is low — re-evaluate for bacterial superinfection (especially post-influenza S. aureus).

4. Stop antibiotics and continue antivirals as indicated

Discontinue antibiotics with a documented stewardship reason; complete the antiviral course (e.g. 5 days oseltamivir, 5-10 days remdesivir). Reassess daily for clinical relapse or secondary infection.

[3] [7]

Critical limitations — a positive PCR is not a diagnosis

Note

Detection of viral RNA/DNA does not prove the virus is causing the pneumonia

This is the single most examined concept in viral CAP. Multiplex PCR detects nucleic acid, not viable virus and not necessarily disease-causing infection. Three phenomena undermine a naïve positive result:

Asymptomatic shedding / carriage — rhinovirus, enterovirus, bocavirus and endemic coronaviruses are frequently detected in healthy, asymptomatic adults and children. A positive result may reflect background carriage rather than the cause of the pneumonia.
Prolonged shedding post-infection — after a resolved viral illness, nucleic acid can be detectable for weeks (influenza up to ~1 week, RSV and hMPV for weeks, adenovirus for weeks-months, SARS-CoV-2 RNA for many weeks in the immunocompromised). A positive result may therefore reflect an infection the patient has already cleared.
Co-infection — a true bacterial pneumonia may coexist with an incidental or contributory viral finding. Post-influenza S. aureus and pneumococcal pneumonia are classic examples. [1]

The practical consequence is unchanged: always cover bacterial infection empirically in severe CAP, and de-escalate only on integrated evidence (cultures, procalcitonin trend, clinical course), never on the viral PCR alone.[1][2]

[1] [9]

Procalcitonin — the bacterial biomarker adjunct

Note

PCT is an adjunct, not an arbiter — interpret it as a trend

Procalcitonin is the peptide prohormone of calcitonin; it rises within hours of bacterial infection (driven by IL-1β/TNF-α and suppressed by interferon-γ from viral infection). This is the biological basis for its use to distinguish bacterial from viral disease: a low PCT (<0.1 ng/mL) supports a viral/non-bacterial process; a high or rising PCT supports bacterial co-infection. A patient-level meta-analysis of >6700 patients showed that PCT-guided algorithms reduce antibiotic exposure in acute respiratory infections without increasing mortality. Two hard caveats for the ICU: (1) PCT can be normal in the first few hours of bacterial sepsis — a single early value does not exclude bacterial infection; (2) in pure viral pneumonia a low PCT does NOT exclude bacterial co-infection, which is common (25-50%). Always interpret PCT as a trend alongside cultures and the clinical course.[7]

The immunocompromised host — broaden the viral net

Note

When the standard panel is not enough — CMV, HSV, and friends

The standard respiratory virus panel covers community-acquired viruses, but opportunistic herpesviruses are a major cause of pneumonitis in the immunocompromised and are NOT on most CAP panels. In haematopoietic stem cell transplant, solid-organ transplant, high-dose corticosteroid/cytotoxic therapy, and advanced HIV (CD4 <50) with interstitial infiltrates and hypoxia, the viral workup must be broader:

CMV PCR on BAL (and quantitative CMV DNAemia) — CMV pneumonitis is classically a stem-cell-transplant disease; treat with ganciclovir 5 mg/kg IV BD x 14-21 days, reduce immunosuppression, consider IVIG in severe disease.
HSV PCR on BAL — HSV-1 tracheobronchitis/pneumonitis in intubated, immunocompromised or burn patients; treat with aciclovir.
Adenovirus PCR with blood DNAemia — severe disseminated disease in transplant recipients; consider cidofovir.
EBV, HHV-6 — less commonly primary pneumonitis, but relevant in the post-transplant differential and to PTLD. [1]

These patients also shed community viruses for far longer (SARS-CoV-2 RNA detectable for months), so a positive respiratory panel result is even harder to interpret — biopsy or a falling viral load on therapy may be needed to prove causation.[1][2]

[1] [2]

SAQ — Severe viral CAP and the respiratory virus panel

SAQ — Severe influenza pneumonia with bacterial co-infection

10 minutes · 10 marks

A 61-year-old man is admitted to ICU in mid-winter with a 3-day history of influenzal prodrome (fever, myalgia, coryza) then rapidly progressive dyspnoea. He is in septic shock (BP 84/50, lactate 3.8), SpO2 88% on 15 L, RR 34, and has bilateral interstitial infiltrates progressing to multilobar consolidation over 12 hours. Nasopharyngeal swab multiplex PCR is positive for influenza A (H1N1). Procalcitonin 2.4 ng/mL. Sputum Gram stain shows gram-positive cocci in clusters.

[1]

SAQ — Severe COVID-19 pneumonia in the ICU

10 minutes · 10 marks

A 58-year-old unvaccinated man with type 2 diabetes and BMI 34 presents with 8 days of COVID-19 symptoms and 3 days of worsening dyspnoea. He requires 10 L/min via HFNC to maintain SpO2 92%, RR 30, CRP 145, D-dimer 1800 ng/mL, ferritin 1200. Chest CT shows bilateral ground-glass predominant infiltrates (greater than 50% involvement). He is not in shock.

[1]

Clinical pearls

High-yield viral CAP points for the CICM/FFICM exam

Respiratory virus PCR panel: send in ALL severe CAP (nasopharyngeal swab or BAL). Multiplex: influenza A/B, RSV, SARS-CoV-2, adenovirus, parainfluenza, hMPV, rhinovirus/enterovirus, coronavirus, bocavirus. Result in ~1 hour.[9]
Viral-bacterial co-infection: 25-50%. ALWAYS add antibiotics empirically until bacterial infection excluded — do not stop on the viral PCR alone.[2]
Detecting viral RNA/DNA ≠ causation: asymptomatic shedding (rhinovirus, bocavirus) and prolonged shedding post-infection (adenovirus, RSV, SARS-CoV-2) are common. Interpret the result in context.[1]
Oseltamivir: give empirically in flu season if influenza suspected (even before PCR). Benefit persists even if started >48h in severe disease.[8]
Dexamethasone 6 mg: RECOVERY — reduces mortality in COVID-19 requiring O2/ventilation. Do NOT give to non-hypoxic COVID patients (possible harm). Corticosteroids can PROLONG influenza shedding — do not extrapolate RECOVERY to non-COVID viral pneumonia.[5]
Remdesivir: benefits EARLY disease (first ~10 days). Limited/no benefit in ventilated patients with established ARDS.[4]
Tocilizumab: IL-6 antagonist (REMAP-CAP) for COVID-19 with rapid respiratory deterioration and systemic hyper-inflammation (raised CRP). Targets the immune phase, not the virus.[6]
COVID-19 coagulopathy: high D-dimer, microthrombi. Prophylactic-dose LMWH recommended (therapeutic only if VTE demonstrated).[5]
Proning: effective for COVID-19 ARDS (same as non-COVID ARDS — PaO2/FiO2 <150).[1]
Procalcitonin: low in viral infection (<0.1 ng/mL), elevated in bacterial (>0.5). Useful adjunct for stewardship — but does NOT exclude bacterial co-infection; interpret as a trend.[7]
Seasonality: influenza/RSV (winter), COVID-19 (year-round, waves), hMPV (late winter/spring).[2]
Infection control: droplet + contact precautions for influenza/RSV; negative-pressure/airborne for aerosol-generating procedures; cohort by organism to preserve single rooms.[3]
CMV pneumonia: immunocompromised (transplant, HIV with CD4 <50). Send CMV PCR on BAL (NOT on the standard CAP panel). Ganciclovir 5 mg/kg IV BD x 14-21 days.[1]
HSV pneumonitis: intubated, immunocompromised or burn patients. Send HSV PCR on BAL. Treat with aciclovir.[1]
Antigen tests have lower sensitivity (50-70% for influenza/RSV in adults) — a negative antigen test does NOT exclude infection; PCR is preferred in the ICU.[9]
Viral culture is too slow (3-14 days) and serology is retrospective (paired IgM/IgG weeks apart) — neither guides acute ICU therapy. PCR is the workhorse.[9]
Ribavirin for RSV: reserved for the immunocompromised/severe infants — teratogenic; administer in a scavenged circuit. Supportive care in immunocompetent adults.[3]
Stewardship: a confident viral diagnosis + negative bacterial cultures + improving patient + reassuring PCT trend → stop antibiotics early. Never de-escalate a deteriorating patient on the viral result alone.[7]
Differential diagnosis: viral pneumonia vs bacterial vs fungal (PCP) vs non-infectious (PE, vasculitis, organising pneumonia, pulmonary oedema).[1]
Vaccination: influenza (annual), COVID-19 (primary series + boosters), pneumococcal, RSV (older adults and pregnancy in some regions).[3]

Red flags

Critical viral CAP points

Always add antibiotics empirically — viral-bacterial co-infection is common (25-50%), and a positive viral PCR does not prove the virus is the cause.[2]
Respiratory PCR in ALL severe CAP during viral season (and in any immunocompromised patient year-round).[3]
Oseltamivir empirically if influenza suspected — do not wait for the PCR in flu season.[8]
COVID-19: dexamethasone 6 mg (if hypoxic) + remdesivir (early) + consider tocilizumab (rapid deterioration + raised CRP).[4][5][6]
Procalcitonin low (<0.1) suggests viral — but does NOT exclude bacterial co-infection. Never stop antibiotics on PCT alone in a sick patient.[7]
Prolonged shedding post-infection: a positive adenovirus/RSV/SARS-CoV-2 result may reflect an infection already cleared — ask about recent illness.[1]
Immunocompromised: broaden the net — send CMV and HSV PCR on BAL (not on the standard CAP panel).[1]
Antigen test negative does not exclude influenza/RSV — use PCR in the ICU.[9]
Corticosteroids can prolong influenza shedding — RECOVERY is COVID-specific; do not extrapolate to non-COVID viral pneumonia.[5]

References

[1]Niederman MS, Torres A. Severe community-acquired pneumonia Eur Respir Rev, 2022.PMID 36517046
[2]Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults N Engl J Med, 2015.PMID 26172429
[3]Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med, 2019.PMID 31573350
[4]Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report N Engl J Med, 2020.PMID 32445440
[5]RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 N Engl J Med, 2021.PMID 32678530
[6]REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 N Engl J Med, 2021.PMID 33631065
[7]Schuetz P, Wirz Y, Werner S, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis Lancet Infect Dis, 2018.PMID 29037960
[8]Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials Lancet, 2015.PMID 25640810
[9]Mahony JB. Molecular diagnosis of respiratory virus infections Crit Rev Clin Lab Sci, 2011.PMID 22185616
[10]Popowitch EB, O'Neill SS, Miller MB. Comparison of the Biofire FilmArray RP, Genmark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP fast multiplex assays for detection of respiratory viruses J Clin Microbiol, 2013.PMID 23486707

In one line

Why the respiratory virus panel matters in the ICU

Note

The shift from 'probably viral, treat supportively' to 'this virus, this drug'

Common respiratory viruses in ICU

Influenza A/B

#1 viral cause

Seasonal (winter). Antigenic drift (annual) and shift (pandemic).
Antiviral: oseltamivir 75 mg PO BD x 5 days (start immediately, even if >48h in severe cases)
Bacterial co-infection: S. aureus (#1, often post-influenza), S. pneumoniae, H. influenzae
Vaccination: annual (best prevention)

SARS-CoV-2 (COVID-19)

Pandemic/ongoing

Antiviral: remdesivir 200 mg day 1 then 100 mg daily x 5-10 days (early disease). Limited benefit in late/ventilated patients.
Anti-inflammatory: dexamethasone 6 mg daily x 10 days (RECOVERY trial — reduces mortality in oxygen/ventilated patients)
Immunomodulator: tocilizumab (IL-6 receptor antagonist) for rapid respiratory deterioration + elevated CRP
Anticoagulation: prophylactic-dose LMWH (unless contraindicated) — COVID-associated coagulopathy

RSV

Infants and elderly

Severe in: infants, elderly, heart/lung disease, immunocompromised
Antiviral: ribavirin (aerosolised) — reserved for the immunocompromised; supportive care mainstay in immunocompetent adults
Palivizumab / nirsevimab (monoclonal antibodies) — prophylaxis for high-risk infants (not treatment)
Bronchodilators, supportive ventilation

Adenovirus

Immunocompromised / military recruits

Can cause severe necrotising pneumonia, especially in transplant recipients and neonates
Treatment: cidofovir (limited evidence) + IV immunoglobulin in severe disease
May shed for weeks after infection (interpret PCR with caution)

Human metapneumovirus (hMPV)

Similar to RSV

Clinically indistinguishable from RSV — bronchiolitis in children, pneumonia in elderly/immunocompromised
No specific antiviral — supportive care is the mainstay
Recognised only since 2001; identified by PCR, not by older antigen methods

Parainfluenza 1-4

Croup / pneumonia

Parainfluenza 1/2 — croup in children; type 3 — bronchiolitis and pneumonia
Pneumonia in the immunocompromised (esp. haematopoietic stem cell transplant) can be severe
Supportive care; DAS181 (sialidase) has limited evidence in immunocompromised pneumonia

Rhinovirus / enterovirus

Common cold pathogens

Usually mild (common cold) but a leading cause of CAP exacerbation in COPD/asthma
Can cause severe pneumonia in the immunocompromised
Frequently detected as asymptomatic carriage — interpret a positive result cautiously

Coronavirus (non-SARS) + bocavirus

Panel additions

Seasonal coronaviruses (229E, OC43, NL63, HKU1) cause mild URI but can precipitate CAP in frail patients
Human bocavirus — frequent co-detection in children; true pathogenicity in adults debated
Supportive care; no specific antiviral

CMV (immunocompromised only)

Transplant / advanced HIV

Not on standard CAP panels — send CMV PCR on BAL in the immunocompromised with interstitial infiltrates
Ganciclovir 5 mg/kg IV BD x 14-21 days (valganciclovir for step-down)
Often coexists with pneumonitis in stem-cell transplant recipients

[1] [2]

The multiplex respiratory virus panel — what it is and how it is used

How the syndromic respiratory PCR panel is used in the ICU

1. Specimen — nasopharyngeal swab (or BAL)

2. Multiplex nucleic-acid amplification (PCR)

3. Result interpretation in context

4. Action — therapy, isolation, stewardship

[9] [10] [9] [10]

Clinical utility of a confirmed viral diagnosis

Note

Four reasons a rapid viral result changes ICU management

Antiviral therapy decisions driven by the panel

Influenza A/B positive → oseltamivir

SARS-CoV-2 positive → severity-stratified COVID therapy

RSV positive + immunocompromised → consider ribavirin

CMV positive (BAL) in immunocompromised → ganciclovir

Ganciclovir 5 mg/kg IV BD x 14-21 days, then valganciclovir for maintenance/step-down. Concurrent CMV DNAemia quantitation guides duration. Often combined with reduction of immunosuppression.

Adenovirus / hMPV / parainfluenza / rhinovirus → mainly supportive

[4] [5] [6] [8]

Antiviral and immunomodulatory evidence (COVID-19 and influenza)

2021

Dexamethasone reduces mortality in COVID-19 patients requiring oxygen or ventilation — RECOVERY

Multicentre, randomised, open-label, platform trial

Population: Hospitalised COVID-19 patients (n > 6000 in the dexamethasone arm)

Key finding

[5]

2020

Remdesivir shortens recovery in early COVID-19 — ACTT-1

Double-blind, randomised, placebo-controlled trial

Population: Hospitalised adults with COVID-19 pneumonia (n = 1062)

Key finding

[4]

2021

Tocilizumab improves survival in critically ill COVID-19 — REMAP-CAP

Randomised, embedded, multifactorial, adaptive platform trial

Population: Critically ill adults with COVID-19 receiving respiratory or cardiovascular organ support

Key finding

Reduced 90-day mortality and more organ-support-free days. Benefit seen in patients with systemic hyper-inflammation (elevated CRP).

[6]

2015

Oseltamivir reduces symptom duration in adults with influenza — meta-analysis of RCTs

Meta-analysis of individual patient data from randomised controlled trials

Population: Adults with confirmed influenza treated within 48 hours of symptom onset

Key finding

Significant reduction in symptom duration; in the subgroup of patients with confirmed influenza and higher risk, reduced lower-respiratory-tract complications and hospitalisation.

[8]

Impact on antibiotic stewardship

Note

A viral diagnosis is a stewardship opportunity — not a licence to stop antibiotics

[7]

Using the viral result for safe antibiotic de-escalation

1. Confirm the bacterial workup is negative

2. Confirm the viral result fits the clinical picture

3. Confirm the patient is clinically improving

4. Stop antibiotics and continue antivirals as indicated

[3] [7]

Critical limitations — a positive PCR is not a diagnosis

Note

Detection of viral RNA/DNA does not prove the virus is causing the pneumonia

Asymptomatic shedding / carriage — rhinovirus, enterovirus, bocavirus and endemic coronaviruses are frequently detected in healthy, asymptomatic adults and children. A positive result may reflect background carriage rather than the cause of the pneumonia.
Prolonged shedding post-infection — after a resolved viral illness, nucleic acid can be detectable for weeks (influenza up to ~1 week, RSV and hMPV for weeks, adenovirus for weeks-months, SARS-CoV-2 RNA for many weeks in the immunocompromised). A positive result may therefore reflect an infection the patient has already cleared.
Co-infection — a true bacterial pneumonia may coexist with an incidental or contributory viral finding. Post-influenza S. aureus and pneumococcal pneumonia are classic examples. [1]

[1] [9]

Procalcitonin — the bacterial biomarker adjunct

Note

PCT is an adjunct, not an arbiter — interpret it as a trend

The immunocompromised host — broaden the viral net

Note

When the standard panel is not enough — CMV, HSV, and friends

CMV PCR on BAL (and quantitative CMV DNAemia) — CMV pneumonitis is classically a stem-cell-transplant disease; treat with ganciclovir 5 mg/kg IV BD x 14-21 days, reduce immunosuppression, consider IVIG in severe disease.
HSV PCR on BAL — HSV-1 tracheobronchitis/pneumonitis in intubated, immunocompromised or burn patients; treat with aciclovir.
Adenovirus PCR with blood DNAemia — severe disseminated disease in transplant recipients; consider cidofovir.
EBV, HHV-6 — less commonly primary pneumonitis, but relevant in the post-transplant differential and to PTLD. [1]

[1] [2]

SAQ — Severe viral CAP and the respiratory virus panel

SAQ — Severe influenza pneumonia with bacterial co-infection

10 minutes · 10 marks

[1]

SAQ — Severe COVID-19 pneumonia in the ICU

10 minutes · 10 marks

[1]

Clinical pearls

High-yield viral CAP points for the CICM/FFICM exam

Respiratory virus PCR panel: send in ALL severe CAP (nasopharyngeal swab or BAL). Multiplex: influenza A/B, RSV, SARS-CoV-2, adenovirus, parainfluenza, hMPV, rhinovirus/enterovirus, coronavirus, bocavirus. Result in ~1 hour.[9]
Viral-bacterial co-infection: 25-50%. ALWAYS add antibiotics empirically until bacterial infection excluded — do not stop on the viral PCR alone.[2]
Detecting viral RNA/DNA ≠ causation: asymptomatic shedding (rhinovirus, bocavirus) and prolonged shedding post-infection (adenovirus, RSV, SARS-CoV-2) are common. Interpret the result in context.[1]
Oseltamivir: give empirically in flu season if influenza suspected (even before PCR). Benefit persists even if started >48h in severe disease.[8]
Dexamethasone 6 mg: RECOVERY — reduces mortality in COVID-19 requiring O2/ventilation. Do NOT give to non-hypoxic COVID patients (possible harm). Corticosteroids can PROLONG influenza shedding — do not extrapolate RECOVERY to non-COVID viral pneumonia.[5]
Remdesivir: benefits EARLY disease (first ~10 days). Limited/no benefit in ventilated patients with established ARDS.[4]
Tocilizumab: IL-6 antagonist (REMAP-CAP) for COVID-19 with rapid respiratory deterioration and systemic hyper-inflammation (raised CRP). Targets the immune phase, not the virus.[6]
COVID-19 coagulopathy: high D-dimer, microthrombi. Prophylactic-dose LMWH recommended (therapeutic only if VTE demonstrated).[5]
Proning: effective for COVID-19 ARDS (same as non-COVID ARDS — PaO2/FiO2 <150).[1]
Procalcitonin: low in viral infection (<0.1 ng/mL), elevated in bacterial (>0.5). Useful adjunct for stewardship — but does NOT exclude bacterial co-infection; interpret as a trend.[7]
Seasonality: influenza/RSV (winter), COVID-19 (year-round, waves), hMPV (late winter/spring).[2]
Infection control: droplet + contact precautions for influenza/RSV; negative-pressure/airborne for aerosol-generating procedures; cohort by organism to preserve single rooms.[3]
CMV pneumonia: immunocompromised (transplant, HIV with CD4 <50). Send CMV PCR on BAL (NOT on the standard CAP panel). Ganciclovir 5 mg/kg IV BD x 14-21 days.[1]
HSV pneumonitis: intubated, immunocompromised or burn patients. Send HSV PCR on BAL. Treat with aciclovir.[1]
Antigen tests have lower sensitivity (50-70% for influenza/RSV in adults) — a negative antigen test does NOT exclude infection; PCR is preferred in the ICU.[9]
Viral culture is too slow (3-14 days) and serology is retrospective (paired IgM/IgG weeks apart) — neither guides acute ICU therapy. PCR is the workhorse.[9]
Ribavirin for RSV: reserved for the immunocompromised/severe infants — teratogenic; administer in a scavenged circuit. Supportive care in immunocompetent adults.[3]
Stewardship: a confident viral diagnosis + negative bacterial cultures + improving patient + reassuring PCT trend → stop antibiotics early. Never de-escalate a deteriorating patient on the viral result alone.[7]
Differential diagnosis: viral pneumonia vs bacterial vs fungal (PCP) vs non-infectious (PE, vasculitis, organising pneumonia, pulmonary oedema).[1]
Vaccination: influenza (annual), COVID-19 (primary series + boosters), pneumococcal, RSV (older adults and pregnancy in some regions).[3]

Red flags

Critical viral CAP points

Always add antibiotics empirically — viral-bacterial co-infection is common (25-50%), and a positive viral PCR does not prove the virus is the cause.[2]
Respiratory PCR in ALL severe CAP during viral season (and in any immunocompromised patient year-round).[3]
Oseltamivir empirically if influenza suspected — do not wait for the PCR in flu season.[8]
COVID-19: dexamethasone 6 mg (if hypoxic) + remdesivir (early) + consider tocilizumab (rapid deterioration + raised CRP).[4][5][6]
Procalcitonin low (<0.1) suggests viral — but does NOT exclude bacterial co-infection. Never stop antibiotics on PCT alone in a sick patient.[7]
Prolonged shedding post-infection: a positive adenovirus/RSV/SARS-CoV-2 result may reflect an infection already cleared — ask about recent illness.[1]
Immunocompromised: broaden the net — send CMV and HSV PCR on BAL (not on the standard CAP panel).[1]
Antigen test negative does not exclude influenza/RSV — use PCR in the ICU.[9]
Corticosteroids can prolong influenza shedding — RECOVERY is COVID-specific; do not extrapolate to non-COVID viral pneumonia.[5]

References

[1]Niederman MS, Torres A. Severe community-acquired pneumonia Eur Respir Rev, 2022.PMID 36517046
[2]Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults N Engl J Med, 2015.PMID 26172429
[3]Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med, 2019.PMID 31573350
[4]Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report N Engl J Med, 2020.PMID 32445440
[5]RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 N Engl J Med, 2021.PMID 32678530
[6]REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 N Engl J Med, 2021.PMID 33631065
[7]Schuetz P, Wirz Y, Werner S, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis Lancet Infect Dis, 2018.PMID 29037960
[8]Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials Lancet, 2015.PMID 25640810
[9]Mahony JB. Molecular diagnosis of respiratory virus infections Crit Rev Clin Lab Sci, 2011.PMID 22185616
[10]Popowitch EB, O'Neill SS, Miller MB. Comparison of the Biofire FilmArray RP, Genmark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP fast multiplex assays for detection of respiratory viruses J Clin Microbiol, 2013.PMID 23486707

Your progress

Why the respiratory virus panel matters in the ICU

Common respiratory viruses in ICU

Influenza A/B

SARS-CoV-2 (COVID-19)

RSV

Adenovirus

Human metapneumovirus (hMPV)

Parainfluenza 1-4

Rhinovirus / enterovirus

Coronavirus (non-SARS) + bocavirus

CMV (immunocompromised only)

The multiplex respiratory virus panel — what it is and how it is used

1. Specimen — nasopharyngeal swab (or BAL)

2. Multiplex nucleic-acid amplification (PCR)

3. Result interpretation in context

4. Action — therapy, isolation, stewardship

Clinical utility of a confirmed viral diagnosis

Influenza A/B positive → oseltamivir

SARS-CoV-2 positive → severity-stratified COVID therapy

RSV positive + immunocompromised → consider ribavirin

CMV positive (BAL) in immunocompromised → ganciclovir

Adenovirus / hMPV / parainfluenza / rhinovirus → mainly supportive

Antiviral and immunomodulatory evidence (COVID-19 and influenza)

Dexamethasone reduces mortality in COVID-19 patients requiring oxygen or ventilation — RECOVERY

Remdesivir shortens recovery in early COVID-19 — ACTT-1

Tocilizumab improves survival in critically ill COVID-19 — REMAP-CAP

Oseltamivir reduces symptom duration in adults with influenza — meta-analysis of RCTs

Impact on antibiotic stewardship

1. Confirm the bacterial workup is negative

2. Confirm the viral result fits the clinical picture

3. Confirm the patient is clinically improving

4. Stop antibiotics and continue antivirals as indicated

Critical limitations — a positive PCR is not a diagnosis

Procalcitonin — the bacterial biomarker adjunct

The immunocompromised host — broaden the viral net

SAQ — Severe viral CAP and the respiratory virus panel

SAQ — Severe influenza pneumonia with bacterial co-infection

SAQ — Severe COVID-19 pneumonia in the ICU

Clinical pearls

Red flags

References

Your progress

Why the respiratory virus panel matters in the ICU

Common respiratory viruses in ICU

Influenza A/B

SARS-CoV-2 (COVID-19)

RSV

Adenovirus

Human metapneumovirus (hMPV)

Parainfluenza 1-4

Rhinovirus / enterovirus

Coronavirus (non-SARS) + bocavirus

CMV (immunocompromised only)

The multiplex respiratory virus panel — what it is and how it is used

1. Specimen — nasopharyngeal swab (or BAL)

2. Multiplex nucleic-acid amplification (PCR)

3. Result interpretation in context

4. Action — therapy, isolation, stewardship

Clinical utility of a confirmed viral diagnosis

Influenza A/B positive → oseltamivir

SARS-CoV-2 positive → severity-stratified COVID therapy

RSV positive + immunocompromised → consider ribavirin

CMV positive (BAL) in immunocompromised → ganciclovir

Adenovirus / hMPV / parainfluenza / rhinovirus → mainly supportive

Antiviral and immunomodulatory evidence (COVID-19 and influenza)

Dexamethasone reduces mortality in COVID-19 patients requiring oxygen or ventilation — RECOVERY

Remdesivir shortens recovery in early COVID-19 — ACTT-1

Tocilizumab improves survival in critically ill COVID-19 — REMAP-CAP

Oseltamivir reduces symptom duration in adults with influenza — meta-analysis of RCTs

Impact on antibiotic stewardship

1. Confirm the bacterial workup is negative

2. Confirm the viral result fits the clinical picture

3. Confirm the patient is clinically improving

4. Stop antibiotics and continue antivirals as indicated

Critical limitations — a positive PCR is not a diagnosis

Procalcitonin — the bacterial biomarker adjunct

The immunocompromised host — broaden the viral net

SAQ — Severe viral CAP and the respiratory virus panel

SAQ — Severe influenza pneumonia with bacterial co-infection